Amerikanische Gesellschaft für Hirudotherapie

Chronic Recurrent Cellulitis

Investigational use for chronic recurrent (non-acute) cellulitis with underlying lymphedema or venous insufficiency.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for chronic cellulitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for chronic recurrent cellulitis is investigational and considered inappropriate.
Welche Evidenz existiert?
Tier C (investigational). No published trials; only theoretical mention. Evidence-based therapy for chronic/recurrent cellulitis: identification and treatment of predisposing factors (lymphedema, tinea pedis, venous insufficiency, obesity), antibiotic prophylaxis (penicillin V 250 mg twice daily) per PATCH trial evidence, compression for lymphedema, treatment of acute episodes with appropriate antibiotics (cephalexin, dicloxacillin, cefadroxil; clindamycin or vancomycin if MRSA suspected). Leech therapy in active or chronic cellulitis is contraindicated as it introduces Aeromonas and disrupts the skin barrier.
Hauptrisiken
  • Severe risk of worsening cellulitis or new bacterial superinfection from leech bites
  • Aeromonas hydrophila infection layered on top of existing bacterial infection
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Sepsis or bacteremia in patients with skin barrier disruption
  • Allergic reaction to leech saliva (uncommon)
  • Worsening lymphedema or venous insufficiency from procedural trauma
  • Delay of evidence-based antibiotic prophylaxis (penicillin V)
  • Risk of necrotizing fasciitis if rapid spread occurs
Wer dies nicht in Betracht ziehen sollte
  • Patients with active cellulitis or any signs of skin infection (absolute contraindication)
  • Patients with severe lymphedema or venous stasis ulcers
  • Patients with diabetes and peripheral arterial disease
  • Immunocompromised patients (HIV, transplant, chemotherapy)
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not been offered antibiotic prophylaxis (penicillin V per PATCH trial)
Was Sie Ihren Kliniker fragen sollten
  • Have I been offered antibiotic prophylaxis (penicillin V 250 mg twice daily per PATCH trial)?
  • Have predisposing factors been addressed (tinea pedis, lymphedema, venous insufficiency, obesity)?
  • Am I a candidate for compression therapy for lymphedema?
  • What evidence specifically supports leech therapy for chronic cellulitis?
  • What is the realistic risk of triggering worse infection with leech bites?
  • Is there an infection-control plan for the bite sites?
  • Should I see infectious disease or vascular medicine instead?
Wann dringende medizinische Versorgung suchen
  • Rapidly spreading redness, severe pain disproportionate to appearance (suspect necrotizing fasciitis — emergency)
  • Crepitus, dusky skin, or bullae (necrotizing soft tissue infection)
  • Fever, chills, hypotension, or confusion (possible sepsis)
  • Spreading redness, warmth, pus, or red streaks beyond initial cellulitis area
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

  • This is NOT FDA-cleared for chronic cellulitis.
  • Theoretical mention does NOT establish safety or efficacy in patients with skin infections.
  • It does NOT substitute for antibiotic prophylaxis (penicillin V per PATCH trial evidence).
  • It does NOT replace addressing predisposing factors (tinea pedis, lymphedema, venous insufficiency).
  • It does NOT mean leech application is safe on infected or post-infectious skin — Aeromonas plus existing flora is a recipe for sepsis.

Clinical Profile

Category
dermatological
ICD-10
L03.90, I89.0, L03.119
Safety tier
high

Evidence Summary

No controlled clinical trial or credible case series has evaluated leech therapy for the prevention of recurrent cellulitis in chronic lymphedema or venous insufficiency; there is no reliable evidence that it reduces recurrence. Any proposed lymphatic or venous decongestive mechanism is speculative and unproven for this indication. Critical safety note: leech therapy is contraindicated during the acute phase of cellulitis because of the risk of Aeromonas (including Aeromonas hydrophila) co-infection from the leech gut flora. Established preventive measures — antibiotic prophylaxis (for example penicillin V or erythromycin) per current infectious-disease guidance, compression, and meticulous skin care — remain the standard. ASH position: any use of leech therapy in this setting is investigational and mechanistic only.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Mumcuoglu KY et al. (2014), n=18

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active acute cellulitis
  • Active deep tissue infection

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Chronic Recurrent Cellulitis — Hirudotherapy Evidence | ASH